/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Monopar Therapeutics Inc Share Price Today: Live Updates & Key Insights

Monopar Therapeutics Inc share price today is $56.45, up 1.05%. The stock opened at $56.31 against the previous close of $57, with an intraday high of $57.53 and low of $54.85.

Monopar Therapeutics Inc Share Price Chart

style
pb-0

Monopar Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Monopar Therapeutics Inc Share Price Performance

$56.45 0.0105(1.05%) MNPR at 13 Mar 2026 02:19 PM Biotechnology
Lowest Today 54.85
Highest Today 57.53
Today’s Open 56.31
Prev. Close 57
52 Week High 105.00
52 Week Low 26.06
Day’s Range: Low 54.85 High 57.53
52-Week Range: Low 26.06 High 105.00
1 day return -
1 Week return -0.15
1 month return +2.94
3 month return -23.94
6 month return +4.66
1 year return +85.37
3 year return +2181.6
5 year return +603.32
10 year return -

Monopar Therapeutics Inc Institutional Holdings

HHG PLC 19.26

RA Capital Management, LLC 9.98

Adage Capital Partners Gp LLC 9.57

Saturn V Capital Management LLC 4.87

Vanguard Group Inc 4.40

ADAR1 Capital Management LLC 3.50

Wellington Management Company LLP 3.38

Siren, L.L.C. 3.18

BlackRock Inc 3.05

Deerfield Management Co 2.55

Vanguard Total Stock Mkt Idx Inv 2.51

TCG Crossover Management, LLC 2.29

Janus Henderson Hrzn Biotec E2 USD 1.93

iShares Russell 2000 ETF 1.69

Polar Capital Biotech S Inc 1.50

Vivo Capital, LLC 1.35

Geode Capital Management, LLC 1.27

State Street Corp 1.08

Fidelity Small Cap Index 0.67

Vanguard Institutional Extnd Mkt Idx Tr 0.64

Alyeska Investment Group, L.P. 0.60

iShares Russell 2000 Growth ETF 0.57

Driehaus Capital Management LLC 0.50

Balyasny Asset Management LLC 0.48

State St Russell Sm/Mid Cp® Indx SL Cl I 0.42

BNY Mellon Sm/Md Cp Gr I 0.41

Northern Trust Corp 0.40

DWS ESG Biotech LC 0.37

iShares Core S&P Total US Stock Mkt ETF 0.35

Vanguard Russell 2000 ETF 0.33

Fidelity Extended Market Index 0.31

Neuberger Small Cap Growth Inv 0.30

Vanguard US Momentum Factor ETF 0.26

Bank of New York Mellon Corp 0.26

Neuberger Berman Small Cap Growth 0.26

Morgan Stanley - Brokerage Accounts 0.24

State St Russell Sm Cap® Indx SL Cl I 0.23

Neuberger Berman Small Cap Growth Tr II 0.18

iShares Micro-Cap ETF 0.18

Schwab Small Cap Index 0.17

Monopar Therapeutics Inc Market Status

Strong Buy: 2

Buy: 2

Hold: 1

Sell: 0

Strong Sell: 0

Monopar Therapeutics Inc Fundamentals

Market Cap 380.91 M

PB Ratio 2.7621

PE Ratio 0.0

Enterprise Value 247.39 M

Total Assets 60.29 M

Volume 105649

Monopar Therapeutics Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:122400 0.1M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:122400 0.1M, FY19:null 0.0M

Annual Net worth FY23:-9484619 -9.5M, FY22:-10494399 -10.5M, FY21:-9079200 -9.1M, FY20:-6222671 -6.2M, FY19:-4125987 -4.1M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:null 0.0M, Q1/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:null 0.0M

Quarterly Net worth Q3/2025:-3437601 -3.4M, Q2/2025:-2453526 -2.5M, Q1/2025:-2624972 -2.6M, Q3/2024:-1304276000 -1304.3M, Q2/2024:-1715309 -1.7M

About Monopar Therapeutics Inc & investment objective

Company Information Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Organisation Biotechnology

Employees 14

Industry Biotechnology

CEO Dr. Chandler D. Robinson M.B.A., M.D., M.Sc.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow